ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck CEO's 2011 Compensation Up 41% At $13.3M

By Peter Loftus Of DOW JONES NEWSWIRES Merck & Co.'s (MRK) leader received compensation valued at $13.3 million for 2011, up 41% from the year before, reflecting his ascension to the drug maker's top post and Merck's ability to exceed certain internal performance targets. Kenneth Frazier, 57, became Merck's chief executive at the beginning of 2011 and chairman of the board in December. He was previously head of Merck's human health business. In a proxy statement filed Thursday with the U.S. Securities and Exchange Commission, Merck said certain elements of Frazier's compensation reflected growth in Merck's sales and adjusted earnings for 2011. In addition, Merck's board considered "his performance, leadership, planning and oversight during a time of continued economic, regulatory and political challenges for the healthcare industry." Earlier this year, Frazier acknowledged that Merck had a tough 2011. The company endured setbacks including negative clinical data for a once-promising heart drug, vorapaxar. Merck's full-year stock price performance lagged behind most of its large-pharmaceutical peers. But Merck of Whitehouse Station, N.J., continued to cut costs and was able to raise its dividend for the first time in seven years in 2011. Frazier said in January he was optimistic about 2012. Frazier's total compensation included: $1.5 million in salary, $3.1 million in stock awards, $3 million in option awards, $3.1 million in non-equity incentive plan compensation, and $2.6 million change in pension value and non-qualified deferred compensation earnings. In its proxy, Merck said the company exceeded internal targets for most elements of a company "scorecard" that is used partly to determine executive compensation. Merck exceeded targets for financial outcomes, customer outcomes and "internal business drivers." However, Merck didn't earn any scorecard points for "people and culture." This element of the scorecard reflects Merck's ability to create "a high-performance, sustainable culture as measured by the results of our annual employee culture survey," the proxy said. Based on results of the employee survey, "the Company failed to score any points in this category," the company said. "To earn points, some improvement over 2010 scores was required. In a year of significant transformation, restructuring and change for our employees, scores decreased slightly on the areas of focus." -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Merck (MRK)
11/25/201508:00:07How Big Could This Drug Be for Opko Health?
11/24/201512:35:00Merck Announces Increased Quarterly Dividend
11/24/201507:41:03This Metric Implies That It Might Be Time to Buy Big Pharma Stocks
11/23/201510:01:03Can Merck & Co. Take Down Gilead Sciences?
11/22/201509:12:02Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting...
11/21/201516:30:00Merck Announces Initial Results for KEYTRUDA® (pembrolizumab...
11/21/201509:04:08Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
11/20/201517:55:00Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer...
11/20/201507:40:02Merck & Co.'s Cholesterol-Buster Program Isn't (Yet) an Exercise...
11/19/201506:30:00Lilly and Merck Expand Immuno-oncology Collaboration with Phase...
11/18/201510:18:035 Things Merck & Co., Inc. Wants You to Know
11/17/201515:52:03Why Novavax Inc Is Moving Higher Today
11/17/201510:59:02Here's Why Advaxis' Stock Gained 11% in October
11/17/201508:00:00New Studies Investigating the Use of KEYTRUDA® (pembrolizumab...
11/16/201509:19:033 High-Yield Dividend Stocks You Don't Have to Babysit
11/16/201508:30:00Merck Announces Presentation of Results from Two Phase 2 Studies...
11/15/201518:00:03Exelixis, Inc. Earnings: Riding the Meteor
11/14/201519:00:00Merck Announces Presentation of Phase 3 Results of Investigational...
11/14/201519:00:00Merck to Release Findings from Integrated Analysis of Six Phase...
11/13/201508:41:03Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations